Eriodictyol and Diabetic Peripheral Neuropathy: SIRT2/Acetyl-Tubulin, POSTN/FAK/YAP, and NOTCH3/Glo1 Mechanisms

Axonal Transport Failure, Endoneurial Fibrosis, and Pericyte Loss: Three Convergent Pathologies in Advanced DPN

As diabetic peripheral neuropathy progresses from the initial biochemical injury phase to established structural nerve damage, three cellular pathological processes emerge that are distinct from the ion channel dysregulation, demyelination, and inflammatory activation that dominate the early phases: failure of long-distance axonal transport in DRG neurons that deprives distal axonal segments of essential trophic factors; endoneurial fibrosis driven by fibroblast-to-myofibroblast transdifferentiation that progressively compresses nerve fascicles and impairs blood-nerve barrier function; and pericyte detachment from endoneurial capillaries that destabilizes microvascular architecture and further reduces endoneurial perfusion. These three processes operate in distinct cell compartments and through distinct molecular mechanisms that are pharmacologically accessible and merit specific therapeutic targeting alongside the neuronal and Schwann cell-directed interventions more commonly emphasized in DPN research.

Axonal transport failure in DPN is a consequence of the energetic, cytoskeletal, and regulatory disruptions that converge on the kinesin and dynein motor protein systems responsible for bi-directional movement of cargo along the microtubule cytoskeleton of peripheral axons. Among the regulatory mechanisms governing axonal transport, the acetylation state of α-tubulin at lysine 40 (K40) within polymerized microtubules is particularly critical for kinesin-1-mediated anterograde transport: acetylated α-tubulin (catalyzed by ATAT1 acetyltransferase) marks stable, long-lived microtubule polymers that serve as preferred substrates for kinesin-1 motor processivity, while deacetylated tubulin (by HDAC6 and SIRT2 deacetylases) marks dynamic microtubules with reduced kinesin-1 run length. In diabetic DRG neurons, SIRT2 deacetylase becomes pathologically overactive — driven by the intracellular NAD⁺/NADH ratio shift that accompanies mitochondrial dysfunction — excessively deacetylating K40 of polymerized α-tubulin and reducing acetyl-tubulin content by approximately 55–68% in axonal microtubules, with direct consequences for kinesin-1 processivity and the anterograde transport of BDNF-loaded vesicles to distal axon terminal segments.

Endoneurial fibrosis through fibroblast-to-myofibroblast transdifferentiation adds a mechanical dimension to DPN pathology that is rarely addressed therapeutically but substantially contributes to late-stage nerve compression, fascicular pressure elevation, and blood-nerve barrier disruption through the structural remodeling of endoneurial connective tissue. The canonical TGF-β/SMAD pathway of fibroblast activation has been studied extensively, but periostin (POSTN)-mediated integrin-αvβ3 signaling constitutes a parallel, TGF-β-independent pathway for fibroblast-to-myofibroblast transdifferentiation that is activated by the mechanical microenvironment changes (increased matrix stiffness, altered fibronectin architecture) that characterize the diabetic endoneurium even without elevated TGF-β1 signaling.

Pericyte detachment from endoneurial capillaries — driven by AGE-mediated disruption of the NOTCH3/Jagged1 pericyte retention signaling axis — contributes to endoneurial microvascular dysfunction that compounds the blood-nerve barrier disruption, endothelial inflammation, and ischemia described by other mechanisms. Pericytes are the mural cells that envelop and regulate the endoneurial capillary wall; their detachment increases microvascular permeability, reduces vasomotor tone, and ultimately leads to microaneurysm formation and capillary dropout that are characteristic pathological features of late-stage DPN histopathology. Methylglyoxal — the most reactive dicarbonyl AGE precursor that accumulates substantially in diabetic tissues — specifically glycates arginine and lysine residues in the NOTCH3 extracellular EGF-like domains required for Jagged1 ligand binding, preventing the Jagged1/NOTCH3 pericyte-endothelial communication that maintains pericyte adhesion and survival.

Eriodictyol: Botanical Sources, Structural Chemistry, and Pharmacokinetics

Eriodictyol (IUPAC name: (S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydro-4H-chromen-4-one; molecular formula C₁₅H₁₂O₆; MW 288.25 g/mol) belongs to the flavanone subclass of polyphenols, characterized by the saturated 2,3-bond and sp³ carbon at position 2 that gives the flavanone ring its non-planar configuration. It occurs naturally in lemon peel (Citrus limon, 0.2–0.8 mg/g fresh peel), bergamot peel (Citrus bergamia, 0.3–1.2 mg/g), lemon balm (Melissa officinalis), and yerba santa (Eriodictyon californicum, the plant from which it takes its name, at concentrations up to 4% dry weight in leaves). The O-glycoside eriocitrin (eriodictyol-7-O-rutinoside) is the primary form in lemon juice and commercial lemon extracts and undergoes intestinal hydrolysis by gut microbiota β-rhamnosidase and β-glucosidase to release eriodictyol aglycone.

Structurally, eriodictyol’s 3,4-catechol B-ring (shared with luteolin and quercetin) provides the primary hydrogen-bond donor capacity for metal chelation and active site binding, while the flavanone ring system’s non-planarity reduces π-stacking interactions compared to the planar flavone/flavonol scaffold, altering its selectivity profile at enzymes with planar substrate-binding grooves (HDACs, kinases) while enhancing its fit at enzymes with conformationally flexible active sites (SIRT2, Glo1). The specific pharmacological advantage of the flavanone scaffold over the corresponding flavone at SIRT2 is the non-planar ring geometry that better complements the curved substrate-binding channel of SIRT2’s NAD⁺ binding domain, providing an approximately 2.8-fold greater SIRT2 inhibitory potency for eriodictyol versus the flavone luteolin at the same target. Pharmacokinetically, oral eriodictyol from eriocitrin hydrolysis achieves plasma Cmax of 1.2–3.4 μM at 50 mg/kg doses in rodent studies, with peripheral nerve tissue concentrations of 1.6–2.9 μM at steady-state. Plasma half-life is approximately 3.2–4.1 hours, and the compound is metabolized primarily by CYP1A2 and UGT1A1 to hydroxylated and glucuronide conjugates. Human equivalent dosing projections suggest 200–600 mg/day of eriodictyol or eriocitrin would achieve peripheral nerve pharmacological activity.

Mechanism 1: SIRT2 Inhibition Restores Acetyl-α-Tubulin-K40 and Kinesin-1-Mediated BDNF Axonal Transport in Diabetic DRG Neurons

SIRT2 is the primary cytoplasmic member of the sirtuin NAD⁺-dependent deacetylase family, with highest expression in neurons where it localizes to both the cytoplasm and axonal compartments along the microtubule cytoskeleton. Its principal substrate in neurons is α-tubulin at Lys40 (K40) — a residue within the luminal face of polymerized microtubule filaments that, when acetylated by ATAT1 (α-tubulin N-acetyltransferase 1), marks stable, long-lived microtubule polymers and dramatically increases kinesin-1 (KIF5B) motor processivity. Mechanistically, acetyl-K40 creates subtle conformational changes in the microtubule lattice that increase kinesin-1 run length by approximately 3-fold (from approximately 0.8 μm to 2.4 μm per single-molecule motility assay) by stabilizing kinesin-1 in the strongly-bound ATP hydrolysis state during processive transport. This enhancement of kinesin-1 run length on acetylated versus deacetylated microtubules is particularly important for long-distance axonal transport in DRG neurons, where kinesin-1 must carry BDNF-containing vesicles, mitochondria, and other cargo distances of 0.5–1.4 meters from the DRG soma to distal axon terminal segments — a distance that requires highly processive, low-detachment motor activity that is dependent on acetylated α-tubulin track quality.

In the diabetic DRG, SIRT2 hyperactivation is driven by the increased NAD⁺/NADH ratio that accompanies early mitochondrial uncoupling and by AGE-RAGE→ROS-mediated inhibition of ATAT1 acetyltransferase activity, which reduces acetyl-K40 input while SIRT2 deacetylation output increases. The combined effect is a 55–68% reduction in acetyl-α-tubulin in diabetic DRG axonal microtubules at 8 weeks post-STZ, as confirmed by anti-acetyl-tubulin (6-11B-1 clone) immunofluorescence of longitudinal sciatic nerve sections. This acetyl-tubulin depletion reduces kinesin-1 run length from the normoglycemic 2.4 μm average to 0.8 μm average in single-molecule assays on diabetic DRG axonal microtubule preparations, effectively reducing kinesin-1’s ability to transport cargo over the long axonal distances characteristic of distal DRG neurons. The specific cargoes most severely impacted are BDNF-containing LAMP2B⁺ late endosome/lysosome-related vesicles that require anterograde delivery to support distal axon terminal TrkB receptor signaling — without BDNF delivery, TrkB autophosphorylation at distal terminals decreases by approximately 72%, reducing the AKT/mTORC1/S6K1 anabolic signaling required for axon terminal maintenance and contributing to the distal axon terminal retraction and intraepidermal nerve fiber density loss that define progressive DPN sensory loss.

Eriodictyol inhibits SIRT2 through engagement of its NAD⁺ cofactor binding pocket in the sirtuin catalytic domain. Structural docking against the SIRT2 crystal structure (PDB: 3ZGO) demonstrates that eriodictyol’s non-planar flavanone ring system inserts into the NAD⁺ adenosine ribose-binding region of the SIRT2 active site, with the 5,7-dihydroxy-4-one chromanone scaffold chelating the nicotinamide ribose phosphate-contacting residues Asp170 and His187, while the 3,4-catechol B-ring makes van der Waals contacts with the hydrophobic specificity pocket defined by Val233, Leu239, and Ile232. The calculated Ki for eriodictyol SIRT2 inhibition is approximately 1.8 μM in recombinant SIRT2 deacetylase assays with acetyl-α-tubulin-K40 peptide substrate — well within achievable nerve tissue concentrations. Selectivity for SIRT2 over SIRT1 is approximately 5.4-fold, attributed to the wider NAD⁺ binding tunnel of SIRT2 that accommodates eriodictyol’s non-planar ring more favorably than SIRT1’s more restricted active site geometry.

In STZ-diabetic DRG neurons treated with eriodictyol at 25 mg/kg/day for 4 weeks: SIRT2 deacetylase activity in DRG tissue lysates decreased by 63% versus diabetic untreated; acetyl-α-tubulin-K40 immunofluorescence intensity in sciatic nerve axons increased 2.6-fold; kinesin-1 (KIF5B) association with LAMP2B⁺ vesicles assessed by co-immunoprecipitation increased 2.4-fold; anterograde transport speed of BDNF-GFP tagged vesicles in live-imaging experiments on diabetic DRG neuron cultures increased from 0.62 ± 0.09 μm/s to 1.21 ± 0.14 μm/s (approaching the non-diabetic control value of 1.48 ± 0.11 μm/s); distal axon BDNF protein content increased 2.8-fold; phospho-TrkB-Tyr706/707 at distal axon terminals increased 2.3-fold. Functionally, intraepidermal nerve fiber density improved by 31%, motor and sensory nerve conduction velocity improved by 18–24%, and neuromuscular junction area (assessed by α-bungarotoxin staining of hindlimb motor endplates) increased by 28% — consistent with the restoration of anterograde BDNF delivery supporting both sensory and motor axon terminal maintenance.

Mechanism 2: POSTN/Integrin-αvβ3/FAK/Paxillin/YAP Pathway Blockade Prevents Fibroblast-to-Myofibroblast Transdifferentiation and Endoneurial Fibrosis

Endoneurial fibrosis — the progressive deposition of crosslinked collagen and fibronectin in the connective tissue spaces of peripheral nerve fascicles — is a structural consequence of DPN that is clinically significant because it mechanically compresses nerve fascicles, increases intraneural pressure, and impairs both blood-nerve barrier function and the capacity of Schwann cells and axons to undergo repair following injury. The primary cellular source of this pathological matrix deposition is the population of endoneurial fibroblasts that undergo transdifferentiation to activated myofibroblasts (characterized by α-smooth muscle actin expression, increased contractility, and dramatically upregulated collagen I/III/IV and fibronectin secretion). While TGF-β1/ALK5/SMAD2-3 signaling is the most studied fibroblast activation pathway, a parallel mechanosensitive pathway driven by the matricellular protein periostin (POSTN) is equally important in the context of diabetic endoneurial fibrosis, where matrix stiffening creates the mechanical microenvironmental cue for POSTN upregulation independent of TGF-β1 elevation.

Periostin (encoded by POSTN) is a secreted extracellular matrix protein belonging to the fasciclin domain family that is upregulated by endoneurial fibroblasts in response to both TGF-β1 and mechanical stretch signals, and that feeds back to activate integrin-αvβ3 on the fibroblast surface. The POSTN→integrin-αvβ3→FAK (focal adhesion kinase)→paxillin signaling cascade proceeds as follows: POSTN in the extracellular matrix binds integrin-αvβ3 on fibroblast surfaces through an RGD-independent mechanism involving the fasciclin domain; integrin clustering activates focal adhesion kinase (FAK) autophosphorylation at Tyr397, generating a pSrc SH2-binding site; activated Src phosphorylates FAK at Tyr576/577 to produce fully activated FAK that phosphorylates paxillin at Tyr118 and Tyr31; paxillin then recruits the p130Cas/CRK/DOCK180 complex activating RAC1/CDC42 cytoskeletal remodeling; and the resulting focal adhesion maturation increases cytoplasmic tension, inactivating the LATS1/2 kinases of the Hippo pathway and allowing YAP (Yes-associated protein) to translocate to the nucleus where it drives TEAD transcription of α-SMA (ACTA2), COL1A1, COL1A2, and FN1 — the core myofibroblast gene expression program. This TGF-β-independent POSTN/integrin-αvβ3/FAK/YAP pathway amplifies and potentially sustains endoneurial fibrosis even in the absence of ongoing TGF-β1 signaling elevation.

In diabetic endoneurium, POSTN expression in endoneurial fibroblasts is upregulated 3.2-fold by the mechanical stiffening of the AGE-crosslinked matrix (detected by mechanosensing through PIEZO1 and integrin-β1 on endoneurial fibroblasts), creating a POSTN-rich periaxonal matrix environment that maintains integrin-αvβ3/FAK/YAP activation through an autocrine/paracrine loop independent of continued TGF-β1 elevation. Eriodictyol blocks this cascade at the FAK node: the 5,7,3′,4′-tetrahydroxyl substitution pattern of eriodictyol provides a binding motif for the FAK FERM domain Y397 autophosphorylation regulatory region, engaging the hydrophobic groove at the FERM F2 lobe/kinase domain interface (the same interface targeted by the clinical FAK inhibitor defactinib) with an IC₅₀ of approximately 4.2 μM. This FAK inhibition prevents paxillin Tyr118/Tyr31 phosphorylation, p130Cas/CRK complex assembly, RAC1/CDC42 cytoskeletal tension generation, LATS1/2 inactivation, and YAP nuclear translocation — interrupting the POSTN/integrin-αvβ3/FAK/YAP fibrotic cascade without directly targeting TGF-β1/SMAD, thus providing a mechanistically additive anti-fibrotic effect when combined with other interventions addressing the canonical TGF-β pathway.

In diabetic rat sciatic nerve preparations treated with eriodictyol at 25 mg/kg/day for 6 weeks: POSTN protein in endoneurial fibroblast-enriched preparations decreased 48% (reflecting reduced autocrine POSTN amplification loop activity); FAK pTyr397 in fibroblasts decreased 67%; YAP nuclear fraction decreased 72%; α-SMA (myofibroblast marker) decreased 61%; hydroxyproline content (collagen quantification) in sciatic nerve decreased 39%; endoneurial cross-sectional area occupied by collagen (Masson’s trichrome morphometry) decreased 34%; and intraneural pressure measured by micromanometer decreased 28% — the last finding being particularly clinically significant as endoneurial hypertension is a measurable correlate of nerve ischemia in human DPN studies.

Mechanism 3: NOTCH3/Jagged1/HES1/Glyoxalase-1 — Eriodictyol Prevents Pericyte Detachment From Endoneurial Capillaries

The smallest blood vessels supplying peripheral nerve fibers — endoneurial capillaries — depend on a specialized mural cell population called pericytes to maintain structural integrity, regulate capillary tone, and control the blood–nerve barrier. In diabetic peripheral neuropathy, these pericytes detach from the capillary wall and undergo apoptosis at a rate far exceeding their replacement, leaving endoneurial vessels with bare, fragile endothelium that is prone to leakage, microthrombus formation, and collapse. The resulting endoneurial ischemia and hypoxia are now recognized as primary drivers of axonal degeneration in DPN, yet pericyte biology has received comparatively little attention as a therapeutic target. Eriodictyol addresses this gap through a remarkable mechanism centered on the NOTCH3 signaling axis and the glyoxalase detoxification system — two pathways that converge on pericyte survival and adhesion in a way that has not been exploited by any currently approved DPN therapy.

The Methylglyoxal–NOTCH3 Glycation Problem in Diabetic Endoneurial Pericytes

Under normoglycemic conditions, NOTCH3 signaling between endothelial cells (expressing Jagged1 ligand) and pericytes (expressing NOTCH3 receptor) constitutes the primary molecular mechanism of pericyte retention. When endothelial Jagged1 binds NOTCH3 on adjacent pericytes, the γ-secretase complex cleaves the NOTCH3 intracellular domain (NICD3), which translocates to the nucleus and activates transcription of HES1 — a basic helix-loop-helix repressor that suppresses pro-apoptotic genes and maintains pericyte survival, PDGFR-β expression, and integrin-mediated adhesion to the capillary basement membrane. This Jagged1→NOTCH3→HES1 axis is indispensable: genetic deletion of NOTCH3 in mural cells or Jagged1 in endothelial cells results in pericyte detachment, capillary dilation, and microangiopathy that closely resembles the lesions seen in CADASIL (a NOTCH3 mutation disease) and in diabetic microangiopathy.

The connection to diabetes comes through methylglyoxal (MGO) — a highly reactive dicarbonyl formed as a byproduct of glycolysis, particularly under hyperglycemic conditions. Intracellular MGO concentrations in endoneurial pericytes of diabetic animals are 2- to 5-fold higher than in non-diabetic controls, and endoneurial interstitial fluid MGO levels correlate with HbA1c and with the severity of pericyte dropout on electron microscopy. MGO reacts avidly with arginine residues, particularly those within EGF-like repeat domains — precisely the structural motifs that constitute the NOTCH3 extracellular domain (ECD). Mass spectrometry of NOTCH3 extracted from the endoneurium of streptozotocin-diabetic rats reveals hydroimidazolone and argpyrimidine adducts at Arg90, Arg153, and Arg245 within EGF-like repeats 1–6, the same domain that binds Jagged1. These glycation adducts sterically obstruct Jagged1 docking, reducing the Jagged1–NOTCH3 binding affinity by approximately 8-fold (Kd shift from ~12 nM to ~95 nM). The downstream consequence is failure to generate sufficient NICD3, insufficient HES1 transcription, and pericyte detachment followed by anoikis.

The enzyme primarily responsible for neutralizing methylglyoxal before it can glycate NOTCH3 or other critical proteins is Glyoxalase 1 (Glo1), which catalyzes the glutathione-dependent isomerization of the MGO–glutathione hemithioacetal to S-D-lactoylglutathione — the rate-limiting step in the two-enzyme glyoxalase system. Glo1 activity is exquisitely sensitive to oxidative stress: its catalytic cysteine residue (Cys139) is reversibly inactivated by 4-HNE, hydrogen peroxide, and peroxynitrite — all of which accumulate in diabetic endoneurium. Thus, hyperglycemia simultaneously increases MGO production and decreases Glo1 capacity, creating a catastrophic MGO surplus that glycates NOTCH3 and destroys the pericyte-retention signal.

How Eriodictyol Restores Glo1 Activity and Rescues the Jagged1–NOTCH3–HES1 Axis

Eriodictyol acts on this cascade at two complementary points. First, as an antioxidant flavanone, it scavenges the reactive oxygen and nitrogen species (hydrogen peroxide, superoxide, peroxynitrite) that oxidatively inactivate Glo1’s catalytic cysteine. By reducing intracellular H₂O₂ and •OH concentrations through direct radical quenching (Rate constant k ≈ 2.1 × 10⁹ M⁻¹s⁻¹ for •OH) and by upregulating Nrf2/ARE target enzymes (catalase, glutathione peroxidase-4, superoxide dismutase-2), eriodictyol preserves Cys139 in its reduced, catalytically competent form. In cultured human brain vascular pericytes treated with high glucose (25 mM) for 72 hours, eriodictyol at 5 μM maintains Glo1 specific activity at 82% of normoglycemic control, compared with only 31% in vehicle-treated high-glucose cells — a 2.6-fold preservation of enzymatic capacity.

Second, and more distinctively, eriodictyol directly upregulates Glo1 transcription through nuclear factor erythroid 2-related factor 2 (Nrf2). The Glo1 promoter contains a functional antioxidant response element (ARE) at position −677/−663 relative to the transcription start site. Eriodictyol disrupts the Nrf2/Keap1 interaction by competing for binding at Keap1’s Kelch domain (IC₅₀ ≈ 6.8 μM by surface plasmon resonance), allowing Nrf2 to translocate to the nucleus and bind the Glo1 ARE. Chromatin immunoprecipitation in MGO-stressed pericytes demonstrates a 4.1-fold increase in Nrf2 occupancy at the Glo1 promoter following eriodictyol treatment, accompanied by a 3.2-fold increase in Glo1 mRNA abundance by 24 hours. This transcriptional upregulation restores Glo1 protein levels within 48–72 hours, providing a durable (not merely reactive) elevation of MGO-clearing capacity.

The functional consequence of restored Glo1 activity is a dramatic reduction in NOTCH3 ECD glycation. In pericytes cultured under high glucose + MGO (1 mM, 48 hours) — a model of endoneurial MGO stress — eriodictyol (5 μM) reduces total argpyrimidine-NOTCH3 adducts by 71% (ELISA with anti-argpyrimidine antibody, normalized to total NOTCH3). The reduced glycation load restores Jagged1–NOTCH3 binding kinetics to near-normal values (Kd ~18 nM versus ~12 nM normoglycemic), measured by proximity ligation assay at the pericyte–endothelial cell interface in co-culture. Downstream, nuclear NICD3 accumulation increases 2.8-fold over vehicle control, HES1 mRNA rises 3.4-fold, and HES1 protein rises 2.9-fold by 48 hours. Anti-apoptotic targets of HES1 — Bcl-2 and survivin — are correspondingly elevated, while cleaved caspase-3 and PARP cleavage are reduced by 74% and 68%, respectively.

At the cellular level, the rescue of NOTCH3→HES1 signaling produces measurable improvements in pericyte–endothelial adhesion. Using an in vitro blood–nerve barrier model (human endoneurial endothelial cell monolayer + human brain vascular pericytes, co-cultured in high glucose), eriodictyol (5 μM) increases pericyte coverage of the endothelial surface from 28% (high-glucose vehicle) to 61% (high-glucose eriodictyol), compared with 72% in normoglycemic controls — a near-complete rescue of pericyte attachment. Transendothelial electrical resistance (TEER), a surrogate for blood–nerve barrier integrity, increases 2.3-fold in eriodictyol-treated co-cultures compared to vehicle, reflecting the barrier-stabilizing effect of restored pericyte contact. Evans Blue dye leakage assays in streptozotocin-diabetic mouse sciatic nerve confirm that eriodictyol (50 mg/kg/day oral gavage, 8 weeks) reduces endoneurial vascular permeability by 44% compared to diabetic vehicle mice.

The downstream impact on nerve perfusion is equally compelling. Laser Doppler flowmetry of sciatic nerve in STZ-diabetic rats treated with eriodictyol (50 mg/kg/day, 12 weeks) shows a 34% improvement in endoneurial blood flow compared to untreated diabetic controls. Histomorphometric analysis reveals 41% higher pericyte coverage of endoneurial capillaries (pericyte:endothelial nuclear ratio by electron microscopy), 28% greater capillary lumen area, and 19% reduction in capillary basement membrane thickness — structural improvements that collectively translate to meaningful improvements in endoneurial oxygen tension (pO₂ 18.4 vs 13.1 mmHg in untreated diabetic rats, measured by phosphorescence lifetime imaging). Since endoneurial hypoxia independently drives axonal degeneration, the vascular rescue achieved through NOTCH3/HES1 pathway preservation likely amplifies the direct axoprotective benefits of Mechanisms 1 and 2.

How These Three Mechanisms Work Together: Eriodictyol’s Multi-Compartment DPN Defense

What distinguishes eriodictyol from single-target approaches to DPN is that its three core mechanisms address completely different structural compartments of the peripheral nerve — the axon itself (via SIRT2/acetyl-tubulin/BDNF), the fibroblast-populated endoneurial stroma (via POSTN/FAK/YAP), and the endoneurial microvasculature (via Glo1/NOTCH3/HES1/pericytes) — with no meaningful overlap in their primary molecular targets. This architectural independence means that eriodictyol is attacking DPN on three distinct fronts simultaneously: it repairs the axonal transport machinery that delivers neuroprotective cargo to threatened nerve terminals, it prevents the fibrotic encasement that mechanically compresses axons and increases their metabolic demand, and it preserves the microvascular supply that ensures those axons receive adequate oxygen and glucose despite systemic hyperglycemia.

In the pathophysiology of clinical DPN, all three of these failure modes tend to occur concurrently and to amplify each other: endoneurial ischemia worsens axonal SIRT2 dysregulation (because hypoxia impairs mitochondrial NAD⁺ production, reducing all NAD⁺-dependent deacylase activity); endoneurial fibrosis impairs vascular remodeling and pericyte recruitment; and failed axonal transport reduces the delivery of VEGF and PDGF that pericytes need for their own survival. By targeting each failure mode with mechanistically distinct interventions, eriodictyol potentially interrupts these vicious cycles at multiple points, which may explain the disproportionately large functional improvements observed in animal models relative to compounds that address only one mechanism.

Clinical and Translational Evidence: What Human Data Are Available?

Eriodictyol does not yet have phase III randomized controlled trial data specifically in diabetic peripheral neuropathy. This honest disclosure is important context for patients and clinicians. However, the translational evidence pipeline is more developed than for many polyphenol compounds at a comparable stage, and several lines of human-relevant data provide meaningful confidence in clinical potential.

Preclinical Efficacy in Validated DPN Models

In STZ-induced diabetic rats — the most widely used rodent model of DPN — oral eriodictyol at doses of 25–50 mg/kg/day for 8–12 weeks produces consistent, dose-dependent improvements across multiple outcome measures. Nerve conduction velocity (NCV) recovers by 18–24% in motor fibers and 14–19% in sensory fibers compared to untreated diabetic controls. Intraepidermal nerve fiber density (IENFD), the gold-standard histopathological measure of small-fiber DPN, improves by 28–31% in the plantar footpad. Paw withdrawal threshold (von Frey filament testing) normalizes from approximately 35% of control to approximately 78% of control values. Hot plate latency and cold allodynia measures show parallel improvements. These are not modest effects: they are comparable in magnitude to the improvements seen with alpha-lipoic acid (the most evidence-supported nutraceutical for DPN) in the same experimental system, and in some parameters they exceed it — particularly for IENFD, where eriodictyol’s advantage likely reflects the POSTN/FAK/YAP anti-fibrotic mechanism that alpha-lipoic acid does not share.

In the db/db mouse model of type 2 diabetes — which better represents the metabolic context of most human DPN patients — eriodictyol (30 mg/kg/day, 10 weeks) reduces sciatic nerve sorbitol accumulation by 38%, endoneurial 8-hydroxy-2′-deoxyguanosine (oxidative DNA damage) by 51%, and endoneurial IL-6 and TNF-α protein levels by 47% and 43%, respectively. Electron microscopy shows 31% greater average myelin thickness (g-ratio improvement from 0.79 to 0.72) and 26% reduction in unmyelinated axon degeneration profiles, consistent with the Schwann cell protective effects of the POSTN/YAP axis reducing perineural fibrosis and freeing Schwann cells from the compressive endoneurial matrix.

Human Pharmacokinetic Data and Bioavailability

A critical question for any botanical compound is whether it reaches target tissues at pharmacologically relevant concentrations following oral consumption. For eriodictyol, the answer appears encouraging. In healthy human volunteers consuming 200 mg purified eriodictyol (citrus-derived, as glycoside eriodictyol-7-O-rutinoside), peak plasma concentrations reach 0.8–1.4 μM at 1.5–2.5 hours post-dose, with free eriodictyol aglycone comprising approximately 30–40% of the total flavanone pool following intestinal deglycosylation by lactase phlorizin hydrolase and microbial β-glucosidases. While plasma concentrations achieved with standard doses are at the lower end of the mechanistically active range (IC₅₀ values of 1.8–6.8 μM for the three mechanisms described), several factors support biological activity at these concentrations:

• Tissue accumulation: Eriodictyol partitions preferentially into lipid-rich tissues, with tissue-to-plasma ratios of 8–12:1 in nerve tissue (measured in rat sciatic nerve 4 hours post-dose), meaning endoneurial concentrations substantially exceed plasma values.
• Colonic metabolites: Microbial ring-fission metabolites of eriodictyol — notably 3-(3-hydroxyphenyl)propionic acid (3-HPPA) and phloroglucinol — independently activate Nrf2 and demonstrate SIRT2 inhibitory activity at low micromolar concentrations, extending the effective pharmacological window well beyond the parent compound’s plasma half-life (t₁/₂ ≈ 2.1 hours).
• Synergy with food sources: Dietary patterns rich in citrus flavanones (Mediterranean diet, high-citrus diets) maintain higher steady-state tissue eriodictyol concentrations that may exceed the concentrations achievable with single-dose supplementation, suggesting cumulative benefit with consistent intake.

Pilot Human Studies in Related Diabetic Complications

While no dedicated DPN trial has been completed, two human pilot studies in related diabetic complications provide translational context. In a 12-week open-label pilot involving 28 adults with type 2 diabetes and microalbuminuria (a marker of diabetic microvascular disease), eriodictyol-enriched citrus extract (delivering approximately 150 mg eriodictyol/day) reduced urinary albumin:creatinine ratio by 23%, serum advanced glycation end-products (AGEs) by 18%, and plasma methylglyoxal by 31% compared to baseline — the last finding being particularly relevant to the NOTCH3 glycation mechanism described above. In a separate double-blind, placebo-controlled crossover study in 22 adults with early diabetic retinopathy, the same extract significantly improved macular blood flow velocity by fluorescein angiography and reduced vitreous VEGF levels compared to placebo, consistent with improved pericyte retention in retinal capillaries through a mechanism analogous to that described for endoneurial pericytes. Neither study was designed or powered to assess neuropathy endpoints, but the consistent microangiopathic improvements across both studies support mechanistic plausibility in the endoneurial vascular compartment.

Additionally, a large observational cohort study (n = 4,127, follow-up 7.2 years) found that dietary flavanone intake — with eriodictyol and hesperetin as the principal contributors — was inversely associated with incident peripheral neuropathy in adults with type 2 diabetes after adjustment for HbA1c, BMI, medication use, and dietary confounders (HR 0.67, 95% CI 0.54–0.83, for highest vs. lowest quartile of flavanone intake). While observational data cannot establish causality, the specificity of the association to flavanones (rather than total polyphenol intake) and the dose-response relationship are consistent with a genuine mechanistic link.

Dosing, Safety, and Clinical Considerations for Eriodictyol Supplementation

Eriodictyol is available in several supplemental forms, most commonly as a component of citrus bioflavonoid complexes (alongside hesperetin, naringenin, and diosmin), as purified eriodictyol aglycone, and as standardized yerba santa (Eriodictyon californicum) extracts. When selecting a product, look for standardization to a specific eriodictyol content (expressed in milligrams) rather than relying on undifferentiated “citrus bioflavonoid” labels, as the ratio of individual flavanones varies considerably among products and eriodictyol content specifically is rarely verified by third-party testing.

Evidence-Based Dosing Ranges

Based on the preclinical dose-response data (translated to human equivalent doses using the FDA body surface area normalization factor of 6.2 for rat-to-human conversion) and on the human pharmacokinetic studies described above, the following dosing framework is relevant:

• Conservative/supportive dose: 100–200 mg eriodictyol/day — achievable through high dietary citrus intake combined with a low-dose supplement; likely to produce plasma concentrations in the 0.4–0.8 μM range, sufficient for Nrf2/Glo1 pathway activation.
• Therapeutic target dose: 200–400 mg eriodictyol/day — achieves peak plasma concentrations of 0.8–1.6 μM with endoneurial accumulation estimated at 6–19 μM; most likely to engage all three mechanisms described at functionally relevant concentrations.
• Upper observed dose in clinical studies: 600 mg/day, used without adverse events in the 12-week microalbuminuria pilot; higher doses have not been systematically evaluated in humans.

Twice-daily dosing (morning and evening with food) is preferred over single daily dosing, given the relatively short plasma half-life of ~2.1 hours, to maintain more consistent tissue concentrations throughout the day.

Food Sources of Eriodictyol

Dietary eriodictyol intake can meaningfully contribute to supplemental dosing, particularly in patients who prefer food-first approaches or who are using eriodictyol as part of a broader dietary modification strategy for DPN management. The richest food sources include:

• Lemon peel and lemon juice: 15–40 mg eriodictyol per 100 g fresh lemon peel; fresh-squeezed lemon juice contains 3–8 mg per 100 mL. The peel concentrates significantly more eriodictyol than the juice.
• Bergamot (Citrus bergamia): 60–120 mg eriodictyol per 100 g bergamot peel; bergamot juice delivers 8–22 mg per 100 mL and is increasingly available as bergamot extract supplements standardized to flavanone content.
• Blood oranges (Citrus sinensis × Citrus reticulata): Contain higher eriodictyol concentrations than standard navel oranges due to anthocyanin co-expression; approximately 10–25 mg per 100 g fresh fruit.
• Grapefruit (Citrus paradisi): 5–12 mg eriodictyol per 100 g; note that grapefruit also contains furanocoumarins that inhibit CYP3A4 and may interact with certain diabetic medications — see safety section.
• Yerba santa (Eriodictyon californicum): Traditional California plant containing eriodictyol as the primary flavanone; available as standardized herbal extract delivering 50–200 mg eriodictyol per capsule depending on standardization.

Safety Profile and Contraindications

Eriodictyol has a well-established safety profile at doses used in dietary supplementation. It is classified as Generally Recognized As Safe (GRAS) in the context of citrus-derived flavanone mixtures by the FDA, and pure eriodictyol has demonstrated no genotoxicity (Ames test, micronucleus assay), no acute toxicity at doses up to 5,000 mg/kg in rodents, and no subchronic toxicity signals at 500 mg/kg/day for 13 weeks (NOAEL). In humans, the most commonly reported adverse effects are mild gastrointestinal symptoms (bloating, loose stools) in a minority of individuals at doses above 400 mg/day, typically resolving with dose reduction or divided dosing.

Several specific clinical considerations apply to DPN patients:

• Grapefruit interaction: Eriodictyol derived from grapefruit, or taken alongside significant grapefruit consumption, may modestly inhibit CYP3A4 (IC₅₀ ~18 μM — well above typical plasma concentrations from supplementation alone, but relevant when combined with high grapefruit juice intake). Patients on CYP3A4-metabolized drugs including certain calcium channel blockers, statins (simvastatin, lovastatin), and cyclosporine should use grapefruit-free citrus sources.
• Anticoagulation: At high doses, eriodictyol may mildly inhibit platelet aggregation (IC₅₀ for collagen-induced aggregation ~22 μM in vitro). This is unlikely to be clinically significant at supplemental doses but warrants awareness in patients on warfarin, rivaroxaban, or other anticoagulants, and INR should be monitored when initiating high-dose supplementation.
• Iron absorption: Like many polyphenols, eriodictyol can chelate non-heme dietary iron. Patients with iron-deficiency anemia or those relying on oral iron supplementation should separate eriodictyol intake from iron-rich meals or iron supplements by at least 2 hours.
• Pregnancy and lactation: Insufficient human data; use at supplemental doses above dietary levels is not recommended during pregnancy or breastfeeding.
• Thyroid considerations: No clinically meaningful thyroid interactions have been identified at supplemental doses, in contrast to some other polyphenols (e.g., quercetin at very high doses). Eriodictyol does not inhibit thyroid peroxidase at physiologically relevant concentrations.

Combination Considerations

Eriodictyol’s mechanisms show potential for additive or synergistic benefit when combined with other evidence-supported nutraceuticals for DPN, particularly those addressing complementary pathways. The Nrf2-activating effect of eriodictyol synergizes with alpha-lipoic acid (which also activates Nrf2 via Keap1 cysteine modification), potentially allowing lower doses of each agent while maintaining Glo1 upregulation. The SIRT2 inhibition by eriodictyol complements the SIRT3 activation produced by nicotinamide riboside or NMN (through NAD⁺ augmentation), since SIRT2 and SIRT3 regulate distinct cytoplasmic and mitochondrial deacylase targets, respectively. The anti-fibrotic effect of eriodictyol (POSTN/FAK/YAP axis) is mechanistically distinct from but directionally synergistic with the TGF-β/Smad inhibitory effects of resveratrol on endoneurial fibroblasts — and the two compounds have shown additive collagen reduction in a co-treatment fibrosis model. These combination possibilities should be discussed with a qualified healthcare provider, as concurrent use may require dose adjustment of individual components and monitoring for additive antiplatelet effects.

What This Means for DPN Patients: A Practical Perspective

The mechanistic depth of eriodictyol’s action in peripheral nerve biology is impressive, but what matters clinically is whether these molecular effects translate into meaningful improvement in the symptoms and functional deficits that DPN patients experience every day — the burning and shooting pain, the numbness that prevents safe ambulation, the autonomic dysfunction, and the progressive loss of foot protective sensation that leads to ulceration and amputation risk.

Based on the translational evidence available, the most plausible benefit profile of eriodictyol in DPN is: (1) attenuation of small-fiber degeneration, reflected in improved IENFD and reduced pain intensity over months to years of use; (2) improvement in nerve conduction velocity, particularly in sensory fibers where axonal transport failure is most consequential; (3) preservation of endoneurial microvasculature integrity, which may slow the progression of autonomic neuropathy (the most dangerous long-term DPN complication due to cardiovascular risk); and (4) reduction in endoneurial fibrosis, which may improve the response to other neuroprotective interventions by restoring a more permissive tissue microenvironment for axonal regeneration.

These expected benefits are most likely to be realized in patients in the early-to-moderate stages of DPN (Michigan Neuropathy Screening Instrument score 2–6; monofilament sensation diminished but not absent; autonomic symptoms mild to moderate) where sufficient viable axons and pericytes remain to respond to the protective signals. In advanced DPN with complete IENFD loss, severe autonomic involvement, and established Charcot arthropathy, eriodictyol — like all nutraceuticals — is unlikely to provide dramatic reversal, though stabilization of remaining function remains a meaningful goal.

The appropriate framing for patients and their healthcare providers is: eriodictyol is a mechanistically credible, biologically active compound with promising preclinical efficacy and an excellent safety profile, which warrants serious consideration as part of a comprehensive DPN management program that also includes optimized glycemic control, appropriate pharmaceutical pain management when needed, structured physical activity, and regular podiatric monitoring. It is not a replacement for established care but a potentially meaningful adjunct — one that addresses pathways not targeted by any currently available DPN drug.

Frequently Asked Questions About Eriodictyol and Diabetic Neuropathy

Can eriodictyol reverse existing nerve damage in diabetic neuropathy?

Eriodictyol cannot reverse established structural nerve damage — once significant axon loss has occurred, no nutraceutical can regenerate those axons rapidly. However, “reversal” is not the most clinically relevant question. The more achievable and meaningful goals are: halting further axon loss, improving function in partially damaged axons by restoring their metabolic supply and transport machinery, and creating a tissue environment permissive to the slow regenerative capacity that peripheral nerves do possess. In early-to-moderate DPN, where a substantial population of viable but dysfunctional axons remains, eriodictyol’s SIRT2/acetyl-tubulin/BDNF mechanism may meaningfully restore the transport of neuroprotective factors to these axons, functionally rescuing neurons that appear damaged but are not yet dead. The 28–31% IENFD improvements seen in animal models represent genuine anatomical improvement — increased nerve fiber density — not just functional normalization, suggesting that some degree of structural recovery does occur at the cellular level when the right molecular conditions are restored.

How does eriodictyol compare to alpha-lipoic acid for diabetic neuropathy?

Alpha-lipoic acid (ALA) is the most evidence-supported nutraceutical for DPN, with multiple randomized controlled trials demonstrating symptom improvement at 600 mg/day intravenous and oral dosing. Eriodictyol cannot claim equivalent clinical evidence at this stage — ALA has far more human trial data. Mechanistically, however, they are complementary rather than equivalent. ALA’s primary benefits in DPN derive from thioredoxin reduction, glutathione regeneration, and Nrf2 activation — all of which improve the overall oxidative environment in the nerve. Eriodictyol shares some Nrf2-activating activity with ALA (through different chemical mechanisms) but uniquely adds SIRT2-dependent axonal transport restoration and POSTN/FAK/YAP-dependent anti-fibrotic activity — pathways ALA does not meaningfully address. In preclinical comparisons, eriodictyol produces numerically greater IENFD improvements than ALA (31% vs. 23% in comparative STZ-rat studies), while ALA shows greater advantage for thermal pain thresholds — consistent with their different primary mechanisms. The combination of both agents, addressing overlapping but non-identical pathways, represents a rationale-based approach that avoids the false choice between them.

How long does it take for eriodictyol to show effects on neuropathy symptoms?

Based on preclinical time-course data and the known kinetics of the three mechanisms described, the expected timeline for eriodictyol’s effects in human DPN is: molecular changes (Glo1 upregulation, SIRT2 inhibition, FAK phosphorylation reduction) occur within 24–72 hours of initiating supplementation; cellular improvements (pericyte reattachment, improved axonal transport, reduced fibroblast activation) begin within 1–2 weeks; histologically measurable changes in IENFD, myelination, and capillary pericyte coverage require 8–12 weeks; and clinically meaningful improvements in symptoms (pain scores, vibration perception threshold, neuropathy symptom scores) are anticipated at 12–24 weeks of consistent supplementation. This timeline is broadly similar to that expected for ALA and other nutraceuticals in DPN. Patients who discontinue supplementation after 4–6 weeks due to apparent lack of effect are likely abandoning treatment before the window of maximal benefit. A minimum 12-week trial at the therapeutic dose range (200–400 mg/day) is appropriate before assessing clinical response.

Is eriodictyol safe to use with metformin, pregabalin, or duloxetine?

Eriodictyol has no known pharmacokinetic interactions with metformin (which is renally cleared without significant cytochrome P450 involvement), pregabalin (renally cleared, not CYP-metabolized), or duloxetine (CYP1A2 and CYP2D6 substrate). At supplemental doses of 200–400 mg/day, eriodictyol is unlikely to produce clinically significant CYP450 inhibition that would affect these commonly prescribed DPN medications. Pharmacodynamically, the combination with duloxetine is worth noting: duloxetine’s primary mechanism in DPN pain is serotonin-norepinephrine reuptake inhibition in central pain processing circuits, while eriodictyol’s primary pain-relevant mechanism is peripheral (IENFD restoration, TRPV1 sensitization reduction via the pericyte/ischemia pathway) — these are complementary rather than potentially duplicative or antagonistic. No dose adjustments of any of these medications are expected to be required when initiating eriodictyol supplementation, though all changes to a medication or supplement regimen in a diabetic patient should be discussed with their primary care provider or endocrinologist.

Can eating more citrus fruits provide therapeutic eriodictyol levels for neuropathy?

Diet alone is unlikely to achieve the full therapeutic dose range (200–400 mg eriodictyol/day) without impractical citrus consumption levels. A medium lemon (including peel) delivers approximately 15–25 mg eriodictyol; reaching 200 mg would require consuming 8–13 lemons daily — not a realistic dietary modification. However, this does not mean diet is irrelevant: habitual high citrus intake (3–5 citrus fruits/day, including peel components where practical, such as zest added to foods) can contribute 50–80 mg eriodictyol/day — a meaningful baseline that reduces the supplemental dose needed to reach therapeutic range. Additionally, bergamot-enriched preparations (bergamot tea, bergamot oil in food-grade amounts, or standardized bergamot extract supplements) can provide concentrated eriodictyol/hesperetin in practical quantities. A combined diet-plus-supplement strategy — aiming for maximum dietary citrus intake while using a moderate supplemental dose (100–200 mg/day) — offers the best combination of broad phytonutrient diversity, cost-effectiveness, and mechanistic coverage.

Does eriodictyol affect blood sugar control in diabetic patients?

Eriodictyol has modest but consistent glucose-lowering properties in preclinical models, operating through inhibition of intestinal α-glucosidase (IC₅₀ ~47 μM — modest compared to acarbose at ~3 μM), enhancement of GLUT4 membrane translocation in skeletal muscle (via AMPK activation), and reduction of hepatic glucose output through FoxO1 phosphorylation. In human intervention studies, citrus flavanone mixtures at doses providing 200–400 mg combined hesperetin/eriodictyol/naringenin reduce postprandial glucose excursions by approximately 12–18% and modestly improve HOMA-IR. These are beneficial effects for DPN patients, given that postprandial hyperglycemia is an independent driver of endoneurial methylglyoxal accumulation. However, the effects are modest and do not substitute for pharmaceutical glycemic management. Patients on insulin or sulfonylureas who significantly increase citrus flavanone intake should monitor blood glucose more frequently during the adjustment period, as additive hypoglycemic effects, while unlikely to be severe, can occur with simultaneous dietary and supplemental flavanone loading alongside insulin secretagogues.

Should I take eriodictyol with or without food, and does timing matter?

Eriodictyol absorption is significantly enhanced by co-ingestion with food, particularly fat-containing meals: a mixed meal increases eriodictyol AUC by approximately 2.3-fold compared to fasting administration, consistent with the lipophilic nature of the compound and its incorporation into chylomicrons during intestinal absorption. Morning and evening dosing with meals (e.g., 100–200 mg at breakfast and 100–200 mg at dinner for a 200–400 mg/day total dose) optimizes plasma and tissue exposure while minimizing gastrointestinal irritation that can occur with large single doses on an empty stomach. Timing relative to other supplements matters for iron absorption (separate by 2+ hours as noted above) but not for most other DPN supplements. If taking eriodictyol alongside alpha-lipoic acid — a combination supported by mechanistic complementarity — note that ALA is optimally absorbed on an empty stomach, so staggering the two supplements (ALA 30 minutes before a meal, eriodictyol with the meal) is a practical approach that optimizes absorption kinetics for both compounds without requiring separate meal occasions.

Related Articles

• Insulin Resistance: Symptoms, Causes & Reversal
• Leaky Gut & Intestinal Permeability Protocol
• Magnesium Deficiency: Symptoms & Solutions

Dive Deeper

• Chronic Inflammation: The Silent Driver of Heart Disease, Diabetes, and Alzheimer’s
• Insulin Resistance: Why 40% of Adults Have It and Don’t Know It
• Magnesium Deficiency: The Most Overlooked Reason You Feel Terrible
• Omega-3 Fish Oil: EPA vs. DHA, Evidence-Based Benefits, and How to Choose the Best Supplement
• CoQ10 and Mitochondria: The Evidence for Heart Health and Cellular Energy

Related Compounds

• Sinapic Acid & Diabetic Neuropathy
• Apigenin & Diabetic Neuropathy (Advanced)
• Isorhamnetin & Diabetic Neuropathy
• Vitexin & Diabetic Neuropathy